联环药业
(600513)
| 流通市值：27.20亿 | | | 总市值：27.20亿 |
| 流通股本：2.85亿 | | | 总股本：2.85亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,644,578,576.25 | 1,126,339,878.99 | 528,459,397.27 | 2,174,100,305.52 |
| 营业收入 | 1,644,578,576.25 | 1,126,339,878.99 | 528,459,397.27 | 2,174,100,305.52 |
| 二、营业总成本 | 1,516,612,393.88 | 1,035,476,886.36 | 481,823,038.52 | 2,016,158,761.63 |
| 营业成本 | 824,022,908.65 | 552,203,143.67 | 268,768,697.52 | 1,127,546,545.19 |
| 税金及附加 | 14,807,669.41 | 10,554,308.38 | 4,617,509.3 | 19,873,558.38 |
| 销售费用 | 459,172,224.37 | 320,984,673.4 | 142,324,485.82 | 591,602,014.6 |
| 管理费用 | 106,058,391.31 | 72,589,400.93 | 42,469,922.28 | 119,520,360.7 |
| 研发费用 | 94,317,179.81 | 67,579,468.48 | 17,743,834.23 | 132,140,716.74 |
| 财务费用 | 18,234,020.33 | 11,565,891.5 | 5,898,589.37 | 25,475,566.02 |
| 其中:利息费用 | 18,910,310.58 | 12,123,272.4 | 5,332,898.77 | 26,688,401.26 |
| 其中:利息收入 | 582,086.05 | 447,127.31 | 216,132.68 | 1,331,448.38 |
| 加:投资收益 | -5,619,978.64 | -4,897,063.55 | -1,008,944.2 | -421,810.19 |
| 资产处置收益 | -700 | - | - | 8,885,605.73 |
| 资产减值损失(新) | -387,662.65 | -55,106.51 | 422,478.46 | -2,555,905.5 |
| 信用减值损失(新) | -4,976,129.62 | -2,553,197.84 | -2,117,606.04 | -3,714,119.9 |
| 其他收益 | 5,501,078.08 | 3,894,680.9 | 2,750,774.1 | 14,636,651.11 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 122,482,789.54 | 87,252,305.63 | 46,683,061.07 | 174,771,965.14 |
| 加:营业外收入 | 26,096.34 | 25,000 | 25,000 | 1,779,869.97 |
| 减:营业外支出 | 529,389.23 | 208,742.96 | 130,000 | 1,519,778.29 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 121,979,496.65 | 87,068,562.67 | 46,578,061.07 | 175,032,056.82 |
| 减:所得税费用 | 14,440,492.06 | 14,387,483.08 | 9,579,462.63 | 23,691,733.11 |
| 六、净利润 | 107,539,004.59 | 72,681,079.59 | 36,998,598.44 | 151,340,323.71 |
| 持续经营净利润 | 107,539,004.59 | 72,681,079.59 | 36,998,598.44 | 151,340,323.71 |
| 归属于母公司股东的净利润 | 92,699,157.34 | 62,887,897.87 | 32,545,358.4 | 135,008,519.87 |
| 少数股东损益 | 14,839,847.25 | 9,793,181.72 | 4,453,240.04 | 16,331,803.84 |
| (一)基本每股收益 | 0.32 | 0.22 | 0.11 | 0.47 |
| (二)稀释每股收益 | 0.32 | 0.22 | 0.11 | 0.47 |
| 八、其他综合收益 | -73,049.96 | -43,210.19 | -81,359.12 | -195,308.71 |
| 归属于母公司股东的其他综合收益 | -73,049.96 | -43,210.19 | -81,359.12 | -195,308.71 |
| 九、综合收益总额 | 107,465,954.63 | 72,637,869.4 | 36,917,239.32 | 151,145,015 |
| 归属于母公司股东的综合收益总额 | 92,626,107.38 | 62,844,687.68 | 32,463,999.28 | 134,813,211.16 |
| 归属于少数股东的综合收益总额 | 14,839,847.25 | 9,793,181.72 | 4,453,240.04 | 16,331,803.84 |
| 公告日期 | 2024-10-30 | 2024-08-30 | 2024-04-30 | 2024-03-06 |
| 审计意见(境内) | | | | 标准无保留意见 |